 Shares of ImmunoGen Inc. IMGN, 1.42 jumped 12.0 in premarket trading on Monday after the company said the Food and Drug Administration accepted an application for its experimental ovarian-cancer treatment. The mirvetuximab soravtansine monotherapy has a Prescription Drug User Fee Act action date of Nov. 28. 